These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 26245658)

  • 1. Ranolazine and its Antiarrhythmic Actions.
    Polytarchou K; Manolis AS
    Cardiovasc Hematol Agents Med Chem; 2015; 13(1):31-9. PubMed ID: 26245658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ranolazine: Electrophysiologic Effect, Efficacy, and Safety in Patients with Cardiac Arrhythmias.
    Shenasa M; Assadi H; Heidary S; Shenasa H
    Card Electrophysiol Clin; 2016 Jun; 8(2):467-79. PubMed ID: 27261835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electrophysiologic basis for the antiarrhythmic actions of ranolazine.
    Antzelevitch C; Burashnikov A; Sicouri S; Belardinelli L
    Heart Rhythm; 2011 Aug; 8(8):1281-90. PubMed ID: 21421082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial.
    Scirica BM; Morrow DA; Hod H; Murphy SA; Belardinelli L; Hedgepeth CM; Molhoek P; Verheugt FW; Gersh BJ; McCabe CH; Braunwald E
    Circulation; 2007 Oct; 116(15):1647-52. PubMed ID: 17804441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Late sodium current inhibition: the most promising antiarrhythmic principle in the near future?
    Frommeyer G; Milberg P; Maier LS; Eckardt L
    Curr Med Chem; 2014; 21(11):1271-80. PubMed ID: 23992336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiarrhythmic properties of ranolazine--from bench to bedside.
    Tzeis S; Andrikopoulos G
    Expert Opin Investig Drugs; 2012 Nov; 21(11):1733-41. PubMed ID: 22916846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Late Sodium Current as an Innovative Antiarrhythmic Strategy.
    Bengel P; Ahmad S; Sossalla S
    Curr Heart Fail Rep; 2017 Jun; 14(3):179-186. PubMed ID: 28455610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The antiarrhythmic effects of ranolazine.
    Foster NJ; Haines DE
    Rev Cardiovasc Med; 2009; 10 Suppl 1():S38-45. PubMed ID: 19898287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on ranolazine in the management of angina.
    Codolosa JN; Acharjee S; Figueredo VM
    Vasc Health Risk Manag; 2014; 10():353-62. PubMed ID: 25028555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A focus on antiarrhythmic properties of ranolazine.
    Vizzardi E; D'Aloia A; Quinzani F; Bonadei I; Rovetta R; Bontempi L; Curnis A; Dei Cas L
    J Cardiovasc Pharmacol Ther; 2012 Dec; 17(4):353-6. PubMed ID: 22492919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ranolazine: an antianginal drug with antiarrhythmic properties.
    Tamargo J; Caballero R; Delpón E
    Expert Rev Cardiovasc Ther; 2011 Jul; 9(7):815-27. PubMed ID: 21809962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrapericardial ranolazine prolongs atrial refractory period and markedly reduces atrial fibrillation inducibility in the intact porcine heart.
    Carvas M; Nascimento BC; Acar M; Nearing BD; Belardinelli L; Verrier RL
    J Cardiovasc Pharmacol; 2010 Mar; 55(3):286-91. PubMed ID: 20075744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ranolazine and Vernakalant Prevent Ventricular Arrhythmias in an Experimental Whole-Heart Model of Short QT Syndrome.
    Frommeyer G; Ellermann C; Dechering DG; Kochhäuser S; Bögeholz N; Güner F; Leitz P; Pott C; Eckardt L
    J Cardiovasc Electrophysiol; 2016 Oct; 27(10):1214-1219. PubMed ID: 27283775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ranolazine in Cardiac Arrhythmia.
    Saad M; Mahmoud A; Elgendy IY; Richard Conti C
    Clin Cardiol; 2016 Mar; 39(3):170-8. PubMed ID: 26459200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Use of Ranolazine as an Antiarrhythmic Agent in Atrial Fibrillation.
    White CM; Nguyen E
    Ann Pharmacother; 2017 Mar; 51(3):245-252. PubMed ID: 27758968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ranolazine reduces atrial fibrillatory wave frequency.
    Black-Maier EW; Pokorney SD; Barnett AS; Liu P; Shrader P; Ng J; Goldberger JJ; Zareba W; Daubert JP; Grant AO; Piccini JP
    Europace; 2017 Jul; 19(7):1096-1100. PubMed ID: 27756767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiarrhythmic properties of ranolazine: A review of the current evidence.
    Gupta T; Khera S; Kolte D; Aronow WS; Iwai S
    Int J Cardiol; 2015; 187():66-74. PubMed ID: 25828315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New treatment options for late Na current, arrhythmias, and diastolic dysfunction.
    Maier LS
    Curr Heart Fail Rep; 2012 Sep; 9(3):183-91. PubMed ID: 22767404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antiarrhythmic therapy in patients with heart failure].
    Faber TS; Zehender M
    Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The electrophysiological properties of ranolazine: a metabolic anti-ischemic drug or an energy-efficient antiarrhythmic agent?
    Cingolani E; Lepor NE; Singh BN
    Rev Cardiovasc Med; 2011; 12(3):136-42. PubMed ID: 22080924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.